Anzeige
Mehr »
Login
Mittwoch, 25.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
BREAKING NEWS: Nachbörsliche Hammermeldung - explodiert die Aktie morgen weiter?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
167 Leser
Artikel bewerten:
(0)

Aeluma, Inc.: CORRECTING and REPLACING: Aeluma Provides Fourth Quarter and Fiscal Year 2024 Results

Issues Guidance For More Than 335% Year-Over-Year Revenue Growth in Fiscal Year 2025

(This release updates the release that was posted earlier on September 24, 2024)

GOLETA, CA / ACCESSWIRE / September 24, 2024 / Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in high performance, scalable technologies for mobile, automotive, AI, defense & aerospace, communication and quantum computing, today provided a corporate update and announced financial results for the fourth quarter and full year of fiscal 2024, ended June 30, 2024.

Recent Company Highlights

  • Record backlog from multiple government and commercial contracts driving revenue growth

  • Won major Department of Defense contract that could bring revenue greater than $11.7 million

  • Won contracts from NASA and the Office of Secretary of Defense to advance technology for space and defense & aerospace applications

  • Achieved ISO 9001:2015 certification for quality management system

  • Expands marketing efforts in mobile, quantum computing, AI, 5G/6G wireless, and biomedical

Management Commentary

"With this fifth consecutive quarter reporting revenue and a strong backlog, we are able to begin offering revenue guidance," said Aeluma Founder and CEO, Jonathan Klamkin, Ph.D. "Multiple contract wins are layering revenue to support Aeluma's R&D and path to commercialization without dilutive measures. We believe this approach positions the Company for profitable growth and will propel our technology to scale while shortening the time to market."

Dr. Klamkin continued, "In addition to the increased traction with government funding, Aeluma has attracted commercial contracts that include small-volume orders, sample evaluations, and development contracts. These successes derive primarily from the automotive, industrial, and defense & aerospace markets. Multiple customers have evaluated our samples and validated the performance of Aeluma's technology. Achieving third party validation is an important milestone in our commercialization path. We are also receiving interest from mobile, quantum computing, AI, 5G/6G wireless, and biomedical companies."

Financial Results

During the quarter ended June 30, 2024, revenue was $279 thousand, compared to $193 thousand in the same quarter last year.

The company incurred a net loss of $987 thousand, or $0.08 per basic and diluted share, for the quarter ended June 30, 2024, compared to a net loss of $1.3 million, or $0.10 per basic and diluted share, for the same quarter last year.

For the full fiscal year 2024, revenue reported was $919 thousand, compared with $193 thousand in the prior year.

The company incurred a net loss of $4.6 million, or $0.37 per basic and diluted share, in fiscal 2024, compared with $5.4 million, or $0.47 per basic and diluted share, in the prior year.

The Company had $1.3 million in cash and cash equivalents as of June 30, 2024, compared to $5.1 million as of June 30, 2023.

On August 5, 2024, the Company entered into note purchase agreements (the "NPA") for an aggregate financing of $1.8 million with five accredited investors ("Investors"). At the first closing under the NPA, which occurred on August 5, 2024, the Company issued to the Investors convertible promissory notes in the aggregate principal amount of $1.8 million to purchase shares of the Company's common stock, par value $0.0001 per share. At a second closing under the NPA, which occurred on August 27, 2024, the Company issued convertible promissory notes to five additional accredited Investors in the aggregate principal amount of $1.345 million for aggregate proceeds of $3.145 million.

The total number of shares outstanding was 12,178,424 as of June 30, 2024.

Revenue Guidance

For the first quarter of fiscal 2025, Aeluma currently expects revenue of approximately $400-470 thousand.

For the full year of fiscal 2025, Aeluma currently expects revenue of approximately $4.0-4.2 million.

These statements are forward looking and actual results may differ materially. Refer to the Forward-Looking Statements section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

Note about Non-GAAP Financial Measures

This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Aeluma believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Aeluma believes that these non-GAAP financial measures provide additional insight into Aeluma's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Aeluma's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation and amortization.

A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

About Aeluma, Inc.

Aeluma (www.aeluma.com) develops novel optoelectronics for sensing and communication applications. Aeluma has pioneered a technique to manufacture semiconductor chips using high-performance compound semiconductor materials on large-diameter substrates that are commonly used for mass-market microelectronics. The technology has the potential to enhance performance and scale manufacturing, both of which are critical for emerging applications. Aeluma is developing a streamlined business model from its headquarters in Santa Barbara, California that has a state-of-the-art manufacturing cleanroom. Its transformative semiconductor chip technology may impact a variety of markets including automotive LiDAR, mobile, defense & aerospace, AR/VR, AI, quantum, and communication. Aeluma differentiates itself with unique semiconductor manufacturing capability, proprietary technology, the ability to perform rapid prototyping, and a broad set of product offerings.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company

Aeluma, Inc.
(805) 351-2707
info@aeluma.com

Investor Contact:

Bishop IR
Mike Bishop
(415) 894-9633
ir@aeluma.com

Aeluma, Inc. and Subsidiary
Consolidated Balance Sheets (unaudited)

June 30, 2024

March 31, 2024

June 30, 2023

Assets

Current assets:

Cash and cash equivalents

$

1,291,072

$

1,874,565

$

5,071,490

Accounts receivable

60,004

147,500

189,239

Deferred compensation, current portion

20,133

24,029

53,034

Prepaids and other current assets

21,637

96,113

19,943

Total current assets

1,392,846

2,142,207

5,333,706

Property and equipment:

Equipment

1,531,494

1,526,590

1,209,656

Leasehold improvements

546,864

546,864

546,864

Accumulated depreciation

(608,630

)

(509,391

)

(300,445

)

Property and equipment, net

1,469,728

1,564,063

1,456,075

Intangible assets

6,833

7,583

9,833

Right of use asset - facility

961,626

992,157

351,013

Deferred compensation, long term portion

-

3,085

-

Other assets

13,014

13,014

13,014

Total assets

$

3,844,047

$

4,722,109

$

7,163,641

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

317,237

$

347,236

$

461,797

Accrued expenses and other current liabilities

180,706

172,648

133,092

Lease liability, current portion

128,743

126,420

162,210

Total current liabilities

626,686

646,304

757,099

Lease liability, long term portion

941,200

974,656

296,452

Total liabilities

1,567,886

1,620,960

1,053,551

Commitments and contingencies

-

-

-

Stockholders' equity:

Preferred stock

-

-

-

Common stock

1,218

1,218

1,282

Additional paid-in capital

15,899,304

15,735,477

15,171,074

Accumulated deficit

(13,624,361

)

(12,635,546

)

(9,062,066

)

Total stockholders' equity

2,276,161

3,101,149

6,110,290

Total liabilities and stockholders' equity

$

3,844,047

$

4,722,109

$

7,163,841

Aeluma, Inc. and Subsidiary
Consolidated Statements of Operations (unaudited)

Three Months Ended

Twelve Months Ended

June 30, 2024

March 31, 2024

June 30, 2023

June 30, 2024

June 30, 2023

Revenue

$

279,268

$

343,894

$

193,339

$

918,554

$

193,339

Operating expenses:

Cost of revenue

233,758

233,585

109,395

619,249

109,395

Research and development

400,254

620,285

207,647

2,506,507

2,531,624

General and administrative

634,286

452,792

1,095,905

2,356,106

3,062,005

Total expenses

1,268,298

1,306,662

1,412,947

5,481,862

5,703,024

Loss from operations

(989,030

)

(962,768

)

(1,219,608

)

(4,563,308

)

(5,509,685

)

Other income (expense):

Sub-lease rental income and other income (expense)

(81

)

(81

)

(89,029

)

-

128,913

Interest income

1,892

198

446

1,013

1,190

Total other income, net

1,811

117

(88,583

)

1,013

130,103

Loss before income tax expense

(987,219

)

(962,651

)

(1,308,191

)

(4,562,295

)

(5,379,582

)

Income tax expense

-

-

-

-

-

Net loss

$

(987,219

)

$

(962,651

)

$

(1,308,191

)

$

(4,562,295

)

$

(5,379,582

)

Loss per share - basic and diluted

$

(0.08

)

$

(0.08

)

$

(0.10

)

$

(0.37

)

$

(0.47

)

Weighted average common shares outstanding - basic and diluted

12,178,424

12,175,195

11,518,154

12,298,355

11,379,480

Book value per share

$

0.19

$

0.25

$

0.48

$

0.19

$

0.48

Aeluma, Inc. and Subsidiary
Reconciliation of GAAP and Non-GAAP Net Loss (unaudited)

Three Months Ended

Twelve Months Ended

June 30, 2024

March 31, 2024

June 30, 2023

June 30, 2024

June 30, 2023

GAAP net loss

$

(987,219

)

$

(962,651

)

$

(1,308,191

)

$

(4,562,295

)

$

(5,379,582

)

Adjustments:

Stock-based compensation - Stock option

163,827

191,844

143,891

732,167

448,444

Consulting and advisory - Restricted stock award

6,981

6,981

215,162

32,900

920,464

Depreciation

99,239

78,663

57,971

308,185

203,458

Amortization

750

750

750

3,000

3,000

Total adjustments to GAAP net loss

270,797

278,238

417,774

1,076,252

1,575,366

Non-GAAP net loss

$

(716,422

)

$

(684,413

)

$

(890,417

)

$

(3,486,043

)

$

(3,804,216

)

GAAP net loss per share - basic and diluted

$

(0.08

)

$

(0.08

)

$

(0.10

)

$

(0.37

)

$

(0.47

)

Adjustment

0.02

0.02

0.02

0.09

0.14

Non-GAAP net loss per share - basic and diluted

$

(0.06

)

$

(0.06

)

$

(0.08

)

$

(0.28

)

$

(0.33

)

Aeluma, Inc. and Subsidiary
Consolidated Statements of Cash Flows (unaudited)

Twelve Months Ended

June 30, 2024

June 30, 2023

Operating activities:

Net loss

$

(4,562,295

)

$

(5,379,582

)

Adjustments to reconcile net loss to net cash used in operating activities:

Issuance of shares for services

-

258,000

Amortization of deferred compensation

32,901

662,464

Stock-based compensation expense

732,167

448,444

Depreciation and amortization expense

311,185

206,458

Change in accounts receivable

129,235

(189,239

)

Change in prepaids and other current assets

(1,694

)

7,719

Change in accounts payable

(144,560

)

347,697

Change in accrued expenses and other current liabilities

48,282

67

Net cash used in operating activities

(3,454,779

)

(3,637,972

)

Investing activities:

Purchase of equipment

(321,838

)

(590,043

)

Payment for leasehold improvements

-

(82,502

)

Net cash used in investing activities

(321,838

)

(672,545

)

Financing activities:

Repurchase of common stock

(4,001

)

-

Proceeds from Private Placement, net of offering costs

-

5,641,485

Net cash (used in) provided by financing activities

(4,001

)

5,641,485

Net change in cash

(3,780,618

)

1,330,968

Cash, beginning of period

5,071,690

3,740,722

Cash, end of period

$

1,291,072

$

5,071,690

SOURCE: Aeluma, Inc.

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.